Table 6.
Daily dose per patient of furosemide at baseline and end of study for double‐blind period, for those patients taking study drug and furosemide, by treatment group for Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) safety population (n = 8432)
| Visit | Statistics | Sacubitril/valsartan (mg) (n = 4203) | Enalapril (mg) (n = 4229) |
|---|---|---|---|
| Baseline | N | 685 | 745 |
| Mean (95% CI) | 56.2 (51.9, 60.5) | 57.1 (53.7, 60.5) | |
| SD | 57.03 | 47.72 | |
| Median | 40.0 | 40.0 | |
| Minimum | 0.0 | 0.0 | |
| Maximum | 1000.0 | 750.0 | |
| End of study | N | 685 | 745 |
| Mean (95% CI) | 67.6 (63.5, 71.7) | 78.8 (73.4, 84.2) | |
| SD | 55.14 | 75.41 | |
| Median | 40.0 | 60.0 | |
| Minimum | 0.0 | 5.7 | |
| Maximum | 500.0 | 1000.0 |
Only oral doses of furosemide are considered in this table. CI, confidence interval; SD, standard deviation